Indivior PLC stock (GB00BYZ0C031): opioid-dependence specialist in the spotlight after latest earnings
Indivior PLC (GB00BYZ0C031) is attracting investor attention due to its recent quarterly performance, particularly its opioid-dependence portfolio led by Sublocade, and ongoing litigation. The specialty pharmaceutical company is focused on transitioning from older formulations to long-acting injectables like Sublocade to drive growth and manage generic competition. Its success is closely tied to US healthcare policy, reimbursement decisions, and its ability to navigate legal and competitive pressures within the addiction treatment market.
Indivior PLC stock (GB00BYZ0C031): Opioid-treatment specialist faces DOJ settlement while preparing US relisting
Indivior PLC has reached an agreement in principle with the US Department of Justice to settle civil claims regarding past marketing practices for its opioid-dependence treatment, Suboxone. Simultaneously, the company is preparing to shift its primary stock listing from London to the United States to better reflect its revenue focus on the US market. These developments aim to resolve legal uncertainties and enhance investor access, particularly for American investors.
Indivior PLC stock (GB00BYZ0C031): Q1 revenue rises on Sublocade momentum
Indivior PLC reported strong double-digit revenue growth in Q1 2026, primarily driven by the continued increase in sales of its opioid use disorder treatment, Sublocade. The company generated approximately $317 million in net revenue, marking a 19% year-over-year increase, and remains focused on expanding its addiction treatment portfolio in North America. Indivior's strategy emphasizes evidence-based therapies like Sublocade, supported by clinical data demonstrating its effectiveness in reducing relapse.
New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization
Two new real-world evidence studies by Indivior Pharmaceuticals Inc. show that adherence to monthly injectable buprenorphine (SUBLOCADE®) significantly reduces the risk of opioid use disorder relapse and lowers healthcare utilization. Patients on this treatment were 3.5 to 8.1 times less likely to return to opioid use and experienced fewer infection-related complications and acute care visits compared to those on other buprenorphine treatments. The findings highlight the importance of sustained treatment in improving outcomes for OUD patients.
Indivior PLC stock (GB00BYZ0C031): opioid-treatment specialist under pressure after US listing plan
Indivior PLC, a specialist in opioid use disorder medications with a primary sales market in the US, is planning a Nasdaq listing while navigating ongoing legal challenges and competitive pressures. The company aims to align its market profile with its US revenue base and broaden access to US healthcare-focused investors. This strategic shift and the company's efforts to grow newer formulations and manage litigation are key factors for investors evaluating the stock.
Indivior PLC stock (GB00BYZ0C031): FDA setback for opioid use disorder injection puts focus on pipel
Indivior PLC faced an FDA Complete Response Letter for its RBP-6000 injectable buprenorphine product, raising concerns about its US growth strategy and competitive landscape in opioid use disorder treatments. This setback highlights the company's reliance on its long-acting injectable pipeline and the evolving regulatory environment for addiction therapies. Despite the challenge, the article emphasizes the continued relevance of Indivior's focus due to the ongoing US opioid crisis and policy efforts to expand treatment access.
Indivior PLC stock (GB00BYZ0C031): opioid treatment specialist updates investors after restating 202
Indivior PLC, a pharmaceutical company specializing in opioid use disorder treatments, has restated its 2023 financial results and provided updates on its governance and US listing plans. The company's core business involves buprenorphine-based therapies, primarily targeting the US market due to the high prevalence of opioid addiction and established reimbursement structures. The stock's performance is significantly influenced by US healthcare policy, regulatory developments, and market acceptance of its long-acting injectable treatments.
Indivior stock (GB00BYZ0C031): What the latest business updates mean
Indivior PLC, headquartered in the United Kingdom, remains a key focus for investors due to its significant exposure to the U.S. opioid-use-disorder treatment market. The company's business model is heavily influenced by prescription trends, payer access, regulatory changes, and past litigation, creating both opportunity and considerable volatility. Investors are closely watching Indivior's sales momentum, market access, and guidance commentary to gauge the sustainability of demand and manage ongoing legal and regulatory headlines.
Indivior PLC stock (US45580R1068): earnings momentum and rising EPS estimates attract attention
Indivior PLC is attracting investor interest due to improving earnings expectations and its focus on addiction treatments, particularly for opioid use disorder. Analysts have raised 2026 EPS estimates from $3.03 to $3.35, signaling confidence in the company's strategy. While facing risks like generic competition and regulatory scrutiny, Indivior aims to achieve sustainable growth through pipeline development, strategic partnerships, and focused capital allocation, making it a key stock for healthcare investors given its US market relevance.
Indivior PLC stock (GB00BYZ0C031): opioid treatment specialist updates investors after US listing mo
Indivior PLC, an addiction treatment specialist, has shifted its primary listing to Nasdaq and continues to see strong demand for its opioid use disorder therapies. The company's strategy focuses on the US market, with Sublocade as its main revenue driver, alongside efforts to expand its pipeline and navigate the complexities of the addiction-treatment landscape. This article provides an overview of Indivior's business model, key products, and the factors making it relevant to US investors, highlighting its position in the intersection of healthcare, public policy, and the response to opioid misuse.
Indivior PLC stock (GB00BYZ0C031): Q1 earnings beat lifts 2026 EPS estimates
Indivior PLC (NASDAQ: INDV), a specialty pharmaceutical company, reported first-quarter earnings that surpassed expectations, leading analysts to increase their 2026 EPS forecasts from $3.03 to $3.35. The stock closed at $38.35 on May 13, 2026, and is drawing attention from US investors given its focus on addiction treatment and primary sales in the US market. The company's core products, Suboxone and Sublocade, continue to drive revenue growth amid rising demand for addiction therapeutics.
Indivior to Participate in Upcoming Investor Conferences
Indivior Pharmaceuticals Inc. announced its participation in two upcoming investor conferences in June 2026. CEO Joe Ciaffoni and CFO Ryan Preblick will host meetings and participate in a fireside chat at the Jefferies Global Healthcare Conference on June 3rd, and also host meetings at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8th. The company, a leader in treatments for opioid use disorder, encourages interested investors to contact conference representatives to schedule meetings.
Naloxone Market to See Booming Growth 2026-2033 | EMERGENT, Indivior PLC, Akorn, Inc
The naloxone market is projected to reach USD 3,370.5 Mn by 2033, growing at a CAGR of 10.8% from USD 1,644.1 Mn in 2026. A new report by Coherent Market Insights provides in-depth analysis of the market dynamics, competitive landscape, and growth opportunities, segmenting it by strength, route of administration, and distribution channel. Key players like EMERGENT, Indivior PLC, and Akorn, Inc. are highlighted, along with regional market insights and forecasts.
Indivior PLC stock (US45580R1068): Analyst EPS estimates rise ahead of earnings
Analyst earnings per share (EPS) estimates for Indivior PLC (US45580R1068) have increased from $3.03 to $3.35 over the past 60 days, ahead of its scheduled earnings release on May 14, 2026. Indivior, specializing in addiction treatment medications like SUBLOXONE, primarily operates in the US market, making its performance closely tied to American healthcare trends. Investors are monitoring the upcoming results for confirmation of growth trajectories in key products.
Fuller & Thaler Asset Mgmt (NASDAQ: INDV) holds 4.53M shares, 3.72%
Fuller & Thaler Asset Management, Inc. has filed an amended Schedule 13G/A, disclosing beneficial ownership of 4,529,583.47 shares of Indivior Pharmaceuticals, Inc. (INDV) common stock, representing 3.72% of the class. The filing indicates sole voting power over 4,351,663.47 shares and sole dispositive power over all 4,529,583.47 shares. This passive investment is below the 5% threshold often monitored by investors for significant changes in control.
Indivior stock (GB00BYZ0C031): Specialty pharma earnings beat signals momentum in addiction treatment
Indivior, a specialty pharmaceutical company, has reported first-quarter earnings that surpassed market expectations, leading to a rise in 2026 EPS estimates from $3.03 to $3.35. This upward revision reflects increasing investor confidence in the company's commercial performance and pipeline advancements in addiction and mental health treatments. Operating primarily in the US market, Indivior is positioned to address a significant public health need, benefiting from stable demand and regulatory support.
Indivior PLC stock (GB00BYZ0C031): Upward EPS estimate revisions signal growth
Analyst estimates for Indivior PLC's 2026 earnings per share have risen from $3.03 to $3.35 over the past 60 days, reflecting optimism in the pharmaceutical sector. This upward revision highlights growing confidence in the company's pipeline and market position, particularly in addiction treatment. Indivior's primary market is the US, where its products address a critical public health crisis.
Indivior stock (GB00BYZ0C031): Specialty pharma leader posts strong Q1 earnings beat
Indivior reported strong first-quarter 2026 earnings, surpassing analyst expectations with $317 million in revenue and $0.96 EPS. The specialty pharmaceutical company, focused on addiction medicine, has consistently beaten estimates, demonstrating solid operational execution. With a market capitalization of $4.74 billion and an attractive forward P/E ratio, Indivior offers exposure to the growing addiction treatment market for US investors.
New York State Teachers Retirement System Invests $3.06 Million in Indivior PLC $INDV
The New York State Teachers Retirement System recently invested $3.06 million in Indivior PLC (NASDAQ:INDV), acquiring 85,251 shares in the fourth quarter. This move reflects growing institutional interest, with other hedge funds like Vanguard Group Inc. also significantly increasing their stakes, pushing institutional ownership to 60.33%. Analysts maintain a "Buy" rating for Indivior, with a consensus price target of $39.33, highlighting positive sentiment for the specialty pharmaceutical company.
Indivior PLC stock (GB00BYZ0C031): $175 million share buyback lifts shares
Indivior PLC announced a $175 million accelerated share repurchase program, causing its Nasdaq-listed stock to rise by approximately 4.6%. This move, part of an existing $400 million share-repurchase authorization, emphasizes the company's commitment to returning capital to shareholders and maintaining a strong balance sheet. The buyback is expected to reduce outstanding shares, potentially boosting earnings per share and return on equity, and reflects investor confidence in Indivior's core addiction-treatment products.
Vanguard Group Inc. Acquires 2,008,078 Shares of Indivior PLC $INDV
Vanguard Group Inc. significantly increased its stake in Indivior PLC, acquiring over 2 million additional shares and bringing its total holdings to 5.47 million shares valued at $196.4 million. Indivior reported strong quarterly earnings and revenue, with analysts maintaining a "Buy" rating and an average price target of $39.33. The stock has shown robust performance, trading near its 52-week high, and insider buying further suggests confidence in the company's prospects.
Indivior PLC stock (GB00BYZ0C031): Opioid addiction treatment specialist faces pricing and regulator
Indivior PLC, a UK-based specialty pharmaceutical company, is facing increasing pressure on its stock due to pricing concerns, regulatory scrutiny, and evolving reimbursement dynamics for its opioid addiction treatments in the United States. Its flagship product, Suboxone Film, remains a core revenue driver, but the company navigates a complex environment with competition from generics and public health initiatives. Indivior offers US investors exposure to a niche healthcare segment with both opportunities and significant regulatory and litigation risks.
Pictet Asset Management Holding SA Has $538,000 Position in Indivior PLC $INDV
Pictet Asset Management Holding SA significantly reduced its stake in Indivior PLC by 92.7% in Q4, now holding 14,982 shares valued at approximately $538,000. Despite this reduction, Indivior maintains a consensus "Buy" rating from Wall Street analysts with an average target price of $39.33, following strong quarterly results and recent analyst target increases. The company reported EPS of $0.96 on $317 million revenue, and currently trades near its 52-week high.
Indivior PLC Stock (GB00BYZ0C031): $175 Million Share Buyback Announced
Indivior PLC has announced a $175 million accelerated share repurchase program with Barclays Bank PLC, part of its existing $400 million buyback authorization. The company expects to receive an initial delivery of 3,717,473 shares, with final settlement by June 2026, without impacting its financial guidance. This move reflects confidence in its financial position and capital allocation, supported by strong earnings, positive analyst sentiment, and a recent inclusion in the S&P SmallCap 600 index.
Indivior launches $175M accelerated share buyback
Indivior, a pharmaceutical company, has launched a $175 million accelerated share buyback program. This initiative is part of an existing $100 million share repurchase plan, indicating the company's commitment to returning capital to shareholders. The buyback is expected to efficiently utilize capital and potentially benefit per-share metrics.
New Study Shows Extended-Release Buprenorphine Safely Delivers Rapid, Clinically Meaningful Reductions in Opioid Use and Supports Abstinence in High-Risk Populations
A new study has revealed that extended-release buprenorphine is effective and safe in rapidly reducing opioid use and supporting abstinence among high-risk populations. The findings suggest a significant clinical benefit for individuals struggling with opioid use disorder, potentially improving treatment outcomes. This information was disseminated by Quantisnow, a platform providing real-time market data and news.
Indivior Announces $175 Million Accelerated Share Repurchase
Indivior Pharmaceuticals, Inc. announced a $175 million accelerated share repurchase (ASR) agreement with Barclays Bank PLC, part of its existing $400 million share repurchase program. The company expects to receive an initial delivery of 3,717,473 shares, with final settlement by the end of June 2026. This move reflects Indivior's confidence in its long-term strategy and commitment to disciplined capital allocation, and is not expected to impact its financial guidance.
Indivior Announces $175 Million Accelerated Share Repurchase
Indivior Pharmaceuticals, Inc. announced a $175 million accelerated share repurchase agreement with Barclays Bank PLC. This ASR is part of an existing $400 million share repurchase program and reflects the company's confidence in its long-term strategy and capital allocation. The company expects to receive an initial delivery of 3,717,473 shares, with final settlement by the end of June 2026, and does not anticipate an impact on its financial guidance.
Indivior stock jumps on $175M share buyback announcement
Indivior PLC announced a $175 million accelerated share repurchase agreement with Barclays Bank PLC, causing its shares to rise by 4.6%. This ASR is part of its existing $400 million share repurchase program and reflects the company's confidence in its long-term strategy and cash flow. Indivior expects the final settlement by June 2026 and does not anticipate an impact on its financial guidance.
Indivior (INDV) 10K Form and Latest SEC Filings 2026
This article provides an overview of Indivior's (INDV) SEC filings, highlighting that the company has submitted over 437 documents since 2022. It details the different types of filings, such as 10-K for annual reports, 8-K for material events, and Form 4 for insider ownership changes, and explains their importance to investors. The most recent filing was a Form 8-K on May 4, 2026, and the annual 10-K was filed on February 26, 2026.
Indivior Announces $175 Million Accelerated Share Repurchase
Indivior (INDV) has initiated a $175 million accelerated share repurchase program with Barclays Bank PLC, part of its existing $400 million buyback authorization. The company expects the ASR to settle by the end of June 2026, without impacting its financial guidance. This move reflects Indivior's confidence in its long-term strategy and cash generation, while retaining $100 million for potential future repurchases.
Indivior Announces $175 Million Accelerated Share Repurchase
Indivior Pharmaceuticals, Inc. announced a $175 million accelerated share repurchase (ASR) agreement with Barclays Bank PLC, part of its existing $400 million share repurchase program. The company will make an upfront payment and receive an initial delivery of 3,717,473 shares, with the final number determined by the volume-weighted average price of its stock. This ASR reflects Indivior's confidence in its long-term strategy and is not expected to impact its financial guidance.
Indivior Announces $175 Million Accelerated Share Repurchase
Indivior Pharmaceuticals Inc. has announced a $175 million accelerated share repurchase agreement with Barclays Bank PLC. This ASR is part of an existing $400 million share repurchase program and reflects the company's confidence in its long-term strategy and capital allocation. Indivior will make an upfront payment and expects to receive an initial delivery of 3,717,473 shares, with final settlement by the end of June 2026.
Indivior starts $175M buyback with 3.7M shares due upfront
Indivior announced a $175 million accelerated share repurchase (ASR) program with Barclays, part of its existing $400 million buyback authorization. The company will make an upfront payment of $175 million and expects an initial delivery of over 3.7 million shares, with final settlement based on VWAP by late June 2026. Indivior stated that this ASR will not affect its previously issued financial guidance, and $100 million remains available for future repurchases under the authorization.
Indivior Announces $175 Million Accelerated Share Repurchase
Indivior Pharmaceuticals Inc. announced a $175 million accelerated share repurchase agreement with Barclays Bank PLC, part of its existing $400 million share repurchase program. This move reflects the company's confidence in its long-term strategy and commitment to capital allocation. Indivior expects an initial delivery of 3,717,473 shares and anticipates final settlement by the end of June 2026, without impacting its financial guidance.
Indivior Earnings Call Highlights SUBLOCADE-Fueled Momentum
Indivior plc (INDV) reported strong Q1 2026 earnings, driven primarily by the exceptional performance of its addiction treatment, SUBLOCADE. The company saw a significant increase in revenue and adjusted EBITDA, leading to raised financial guidance for 2026, despite some setbacks in early-stage R&D projects. Management's focus on cost control, a stronger balance sheet, and effective commercial strategies cemented an upbeat outlook for the company's near to medium-term financial trajectory.
Indivior Q1 2026 Earnings Call Transcript
Indivior reported strong Q1 2026 results, with total net revenue up 19% year-over-year, driven by a 32% increase in SUBLOCADE sales. The company raised its full-year 2026 financial guidance, anticipating SUBLOCADE revenue between $950-$990M and Adjusted EBITDA of $620-$660M. Indivior also reprioritized its pipeline, discontinuing internal development for INDV-6001 and INDV-2000, while maintaining U.S. commercial rights for INDV-6001 and exploring external business development for INDV-2000.
Indivior stock hits all-time high at 38.14 USD
Indivior PLC's stock reached an all-time high of $38.14, representing a 197% surge over the past year and reflecting strong investor confidence with a market capitalization of $4.16 billion. The company reported robust Q1 2026 financial results, with EPS of $0.96 and revenue of $317 million, significantly exceeding expectations. While trading near its 52-week high, InvestingPro analysis suggests the stock is currently slightly overvalued relative to its Fair Value.
Indivior Pharmaceuticals Inc. (INDV) Q1 Earnings and Revenues Beat Estimates
Indivior Pharmaceuticals Inc. (INDV) reported strong Q1 2026 results, surpassing Zacks Consensus Estimates for both earnings and revenues. The company posted diluted earnings of $0.96 per share against an estimate of $0.64, and revenues of $317 million, exceeding the $266 million estimate. Despite favorable estimate revisions and a Zacks Rank #2 (Buy), the stock has underperformed the S&P 500 year-to-date.
Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
Indivior Pharmaceuticals Inc. reported strong first-quarter 2026 financial results, with total net revenue up 19% year-over-year to $317 million, driven by a 32% increase in SUBLOCADE® net revenue to $232 million. The company raised its full-year 2026 guidance, now expecting total SUBLOCADE net revenue growth of 13% and adjusted EBITDA growth of 50% year-over-year. Indivior also announced a share repurchase program and completed a $500 million convertible senior notes offering, while discontinuing internal development for two pipeline assets, INDV-6001 and INDV-2000.
Indivior earnings on deck: Can SUBLOCADE momentum continue? By Investing.com
Indivior is set to report its first-quarter earnings, with analysts expecting a significant jump in EPS driven by the success of its SUBLOCADE therapy. Investors will be closely watching for continued momentum in SUBLOCADE dispense unit growth and evidence that the company's restructuring program is boosting margins. Strategic moves like a share repurchase program and redomiciliation to the US also signal management confidence, but operational execution will be key to justifying the stock's current valuation.
Indivior (INDV) Q3 2024 earnings summary
Indivior (INDV) reported a 13% year-over-year increase in Q3 2024 net revenue, reaching $307 million, driven by strong SUBLOCADE sales and patient growth. The company achieved a 62% rise in adjusted operating profit to $97 million and affirmed its FY 2024 net revenue guidance of $1.125–$1.165 billion. A preliminary settlement was reached for legacy antitrust cases, incurring a provision of $39–$40 million.
Indivior PLC stock (GB00BYZ0C031): Why Google Discover changes matter more now for addiction treatme
The Google Discover 2026 Core Update is significantly altering how investors receive information about Indivior PLC (GB00BYZ0C031), a London-listed pharmaceutical company specializing in addiction and schizophrenia treatments. This update provides personalized, mobile-optimized content on Indivior's financial performance, product pipeline (SUBLOXONE, PERSERIS, OPNT003), and market position directly to investors without requiring explicit searches. The shift prioritizes high-density, E-E-A-T-rich content, offering proactive alerts on market trends, competitive pressures, and regulatory updates, thereby giving investors a quicker edge in tracking the company's developments.
Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder
Indivior Pharmaceuticals presented new real-world data at the ASAM 2026 Annual Conference, highlighting the effectiveness of its monthly injectable buprenorphine (SUBLOCADE) for opioid use disorder (OUD). The data supports recognizing remission as a comprehensive treatment outcome and indicates that SUBLOCADE significantly reduces the risk of non-fatal and fatal overdoses compared to no treatment. These findings reinforce the importance of sustained, evidence-based medication-assisted treatment for lasting recovery.
Indivior PLC stock (GB00BYZ0C031): Is its opioid treatment focus strong enough for steady investor returns?
Indivior PLC specializes in addiction treatments, particularly for opioid use disorder, positioning itself in the expanding behavioral health sector. The company's core business model focuses on patented medications with novel delivery technologies, primarily generating revenue in North America but with global scalability. While facing competitive and regulatory pressures, Indivior aims for steady investor returns by focusing on unmet needs in addiction treatment and leveraging strategic partnerships.
Does Indivior (INDV) Survey Support For Long-Acting Buprenorphine Strengthen Its Criminal Justice Strategy?
Indivior PLC announced survey results showing correctional leaders support long-acting injectable buprenorphine for opioid use disorder treatment in jails and prisons, viewing it as a practical solution to staffing and coordination challenges. This support reinforces Indivior's investment thesis for its SUBLOCADE treatment within the criminal justice system and aligns with previous findings on cost-effectiveness, potentially aiding revenue growth and operating leverage. While bullish analysts might see this as reinforcing their revenue and earnings forecasts, investors should also consider the risks associated with market underpenetration and the dependence on long-acting injectables.
Does Indivior (INDV) Survey Support For Long-Acting Buprenorphine Strengthen Its Criminal Justice Strategy?
A recent national survey revealed that correctional leaders identify staffing and coordination challenges as key barriers to preventing opioid use disorder medication diversion. They view long-acting injectable buprenorphine as a practical solution to enhance treatment in jails and prisons. This support could bolster Indivior's broader investment narrative, reinforcing the potential for its treatment, SUBLOCADE, within the criminal justice system.
Survey of Correctional Facility Staff: Monthly Opioid Treatment Shot May Help Reduce Medication Misuse
A national survey published in the Journal of Correctional Health Care indicates that correctional leaders see long-acting injectable (LAI) buprenorphine as a potential strategy to reduce medication diversion and improve opioid use disorder (MOUD) treatment in jails and prisons. The survey, funded by Indivior and conducted with NCCHC, revealed that while a strong majority of correctional professionals believe LAI buprenorphine can help reduce diversion, cost and limited access remain barriers. These findings highlight the need for policies and funding to address staffing, coordination, and sustainable MOUD delivery in correctional settings.
Indivior PLC Survey Highlights Correctional Leaders' Support for Long-Acting Injectable Buprenorphine to Mitigate MOUD Diversion
A national survey funded by Indivior PLC and published in the Journal of Correctional Health Care reveals that correctional leaders view long-acting injectable (LAI) buprenorphine as a key strategy to reduce medication diversion for opioid use disorder (MOUD) in jails and prisons. While respondents largely support its use and recognize its potential to simplify treatment delivery and improve adherence, they also identified significant barriers such as inadequate staffing, poor coordination, cost, and limited access. The findings emphasize the need for policies and funding to address these systemic issues to effectively implement MOUD programs within the criminal justice system.
Indivior (INDV) Proxy filing Summary
Indivior achieved strong financial results in 2025, with net revenue up 4% to $1.24B and SUBLOCADE revenue up 13% to $856M, leading to a 30x increase in GAAP net income to $210M. The company completed Phase I of its Action Agenda and plans to accelerate SUBLOCADE growth. Indivior also resolved a legacy DOJ matter, enabling a $400M share repurchase program, and transitioned to U.S. incorporation and Nasdaq listing.
